Ligand Pharmaceuticals (LGND) Consolidated Net Income (2010 - 2026)
Ligand Pharmaceuticals recorded quarterly Consolidated Net Income of -$13.3 million in Q1 2026, down 129.8% quarter-over-quarter from $44.8 million in Q4 2025, and up 68.56% year-over-year from -$7.9 million in Q1 2025.
Ligand Pharmaceuticals' Consolidated Net Income history runs 15 years deep, the most recent figure standing at -$13.3 million for Q1 2026.
- In Q1 2026, Consolidated Net Income rose 68.56% year-over-year to -$13.3 million; the TTM figure through Mar 2026 stood at $153.6 million (up 308.81% YoY), while the FY2025 annual figure was $124.5 million, up 3186.63% from the prior year.
- Consolidated Net Income came in at -$13.3 million for Q1 2026 at Ligand Pharmaceuticals, down from $44.8 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $117.3 million in Q3 2025 to a low of -$42.5 million in Q1 2025.
- A 5-year average of $4.6 million and a median of -$3.0 million in 2022 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income slumped 136.03% in 2022 and soared 244.06% in 2025, its largest moves.
- Ligand Pharmaceuticals' Consolidated Net Income stood at -$3.0 million in 2022, then jumped by 43.58% to -$1.7 million in 2023, then plunged by 1767.15% to -$31.1 million in 2024, then jumped by 244.06% to $44.8 million in 2025, then slumped by 129.8% to -$13.3 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$13.3 million, $44.8 million, and $117.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn | -13.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.35 Mn |
| Dec 31, 2025 | 44.78 Mn |
| Sep 30, 2025 | 117.27 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | -42.45 Mn |
| Dec 31, 2024 | -31.09 Mn |
| Mar 31, 2023 | -1.67 Mn |
| Dec 31, 2022 | -2.95 Mn |
| Sep 30, 2022 | -9.24 Mn |
| Jun 30, 2022 | -13.49 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -2.22 Mn |
| Sep 30, 2021 | -6.62 Mn |
| Jun 30, 2021 | -5.72 Mn |
| Mar 31, 2021 | -4.66 Mn |
| Dec 31, 2020 | 17.59 Mn |
| Sep 30, 2020 | -6.70 Mn |
| Jun 30, 2020 | 22.09 Mn |
| Mar 31, 2020 | -24.13 Mn |
| Dec 31, 2019 | -7.37 Mn |
| Sep 30, 2019 | -15.25 Mn |
| Jun 30, 2019 | -14.42 Mn |
| Mar 31, 2019 | 666.34 Mn |
| Dec 31, 2018 | -42.48 Mn |
| Sep 30, 2018 | 67.36 Mn |
| Jun 30, 2018 | 73.16 Mn |
| Mar 31, 2018 | 45.28 Mn |
| Mar 31, 2016 | 731,000.00 |
| Dec 31, 2015 | 6.34 Mn |
| Sep 30, 2015 | 199.17 Mn |
| Jun 30, 2013 | 2.40 Mn |
| Mar 31, 2013 | 191,000.00 |
| Dec 31, 2012 | -1.52 Mn |
| Jun 30, 2012 | 1.80 Mn |
| Mar 31, 2012 | 1.87 Mn |
| Sep 30, 2011 | -1,000.00 |
| Mar 31, 2011 | 4,000.00 |
| Dec 31, 2010 | 2.16 Mn |
| Sep 30, 2010 | 12,000.00 |
| Jun 30, 2010 | 7,000.00 |